Valsartan Lawsuit Information
Valsartan lawsuits allege that the blood pressure medication can be contaminated with a substance called N-nitrosodimethylamine (NDMA), which is classified as a probable human carcinogen, meaning exposure to it can cause cancer. In May 2018, the European Medicines Agency began reviewing valsartan-containing medications supplied by the Chinese company Zhejiang Huahai Pharmaceuticals, after NMDA was detected in the valsartan it was supplying to manufacturers in the European Union. In July 2018, the FDA announced that three companies were voluntarily recalling their valsartan medications supplied by Zhejiang Huahai Pharmaceuticals, after detecting the presence of NDMA in the medications. It is believed that the NDMA contamination in question could have begun as early as 2012, when Zhejiang Huahai Pharmaceuticals changed its manufacturing process.
In August 2018, the FDA announced a recall of certain batches of valsartan produced by India-based company Hetero Labs Limited, due to the presence of NDMA, and Torrent Pharmaceuticals also announced the recall of 14 lots of Valsartan/Amlodipine/HCTZ tablets due to NDMA contamination. The FDA action came after 22 other countries recalled 2,300 batches of valsartan supplied to Germany, Finland, Sweden, Norway, Ireland, Hungary, the Netherlands, Austria, Bulgaria, Spain, Belgium, Bosnia, Canada, Greece, Poland, Croatia, Italy, Portugal, France, Lithuania, and Herzegovina, Bahrain and Malta. In the aftermath of the valsartan recall, attorneys across the country are investigating claims on behalf of patients who suffered serious health consequences as a result of taking valsartan contaminated by NDMA.